Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (FINCH 1)

NCT02889796 PHASE3 COMPLETED Results posted

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

Details

Lead sponsor	Gilead Sciences
Phase	PHASE3
Status	COMPLETED
Enrolment	1759
Start date	Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 20 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Rheumatoid Arthritis

Interventions

• Filgotinib
• Placebo to match filgotinib
• Adalimumab
• Placebo to match adalimumab
• MTX

Countries

Hong Kong, Italy, Japan, Taiwan, Ireland, Poland, South Korea, New Zealand, Netherlands, Russia, Belgium, Mexico, Thailand, Bulgaria, Czechia, United States, South Africa, Slovakia, Serbia, Israel, Hungary, Argentina, Canada, Romania, Spain, Ukraine, United Kingdom, Germany, Australia, India